Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Dario Kivelevitch
Bobbak Mansouri
Alan Menter
Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA

Abstract: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.

Keywords: psoriasis, psoriatic arthritis, etanercept, biological therapy, tumor necrosis factor, safety

Introduction

Psoriasis (PsO) is an immune-mediated chronic disease that can affect both the skin and joints. It is characterized by well demarcated, erythematous plaques with an overlying silvery scale classically distributed on the extensor surfaces, scalp, and trunk, although it can affect any area of the skin (Figure 1). Approximately 1% to 3% of the population suffers from PsO.1 Plaque PsO is the most common clinical form affecting approximately 80% of PsO patients.2 Other forms of PsO include guttate, pustular (generalized and localized), erythrodermic, and palmoplantar disease. PsO has been associated with a number of comorbid conditions including the metabolic syndrome, cardiovascular disease, inflammatory bowel disease, anxiety, depression, and of course psoriatic arthritis (PsA). PsA is a seronegative arthritis affecting up to 30% of patients with plaque PsO and has multiple clinical presentations.3,4 It is typically classified into five subtypes: asymmetric oligoarticular arthritis, symmetric polyarthritis, distal interphalangeal arthritis, spondylitis with or without sacroiliitis, and arthropitis mutilans. Physical findings in patients with PsA can also include enthesitis and dactylitis (Figure 2). The most common form of PsA is asymmetric, although any of these types of PsA can erode and destroy...
affected joints leading to loss of functional abilities and a considerable decline in quality of life.5

Treatment of psoriatic skin disease is based on disease severity and includes topical therapies for milder patients, phototherapy for mild to moderate disease, and oral systemic and biological agents in patients with moderate to severe skin disease. These therapeutic strategies can be used as monotherapy or in various combinations. Similarly, PsA treatment is based on disease severity and response to therapy and includes nonsteroidal anti-inflammatory drugs for milder cases and disease-modifying antirheumatic drugs, such as methotrexate and other immunosuppressants, and anti-tumor necrosis factor (TNF-α) as well as the newer anti-interleukin (IL)-12/23p40 agents (ustekinumab) for more severe forms.

Biological therapies have revolutionized the management of PsO and PsA. In 1984, Köhler, Milstein, and Jerne were given the Nobel Prize in Physiology or Medicine for developing this novel technology (nobelprize.org). Since then, a myriad of biological therapies have been created to treat a number of inflammatory, immune-mediated diseases. Biological therapies include monoclonal antibodies as well as recombinant fusion receptor proteins, such as etanercept.

TNF-α plays a major role in the pathophysiology of both PsO and PsA.6 TNF-α levels are elevated in psoriatic skin lesions, serum samples, and synovial fluid.3 Anti-TNF-α therapy has shown efficacy in treating psoriatic skin lesions, joint pain and swelling, enthesitis, and dactylitis plus the ability to improve mobility, reduce radiographic progression of disease, and influence quality of life parameters.7 TNF-α inhibitors which are currently approved to treat PsO and PsA include etanercept, adalimumab, and infliximab while two additional anti-TNF-α agents, golimumab and certolizumab, are only approved for use in PsA.

Etanercept was the first TNF-α inhibitor to be approved for use in PsO and PsA. It is a dimeric, soluble fusion protein consisting of the extracellular ligand binding portion of the TNF receptor linked to the Fc portion of human IgG1 (Figure 3). It is capable of binding and neutralizing soluble TNF and transmembrane TNF.8 Furthermore, it alters neutrophil migration and dendritic cell and T-cell maturation and migration, thus decreasing the local and systemic production of pro-inflammatory cytokines and their subsequent effects.8,9 Etanercept was synthesized in the early 1990s10 and first tested in humans in 1992.11 In 2002 and 2004, etanercept was approved by the United States Food and Drug Administration for the treatment of PsA and in adult PsO patients, respectively.12 The recommended regimen for etanercept for patients with PsO is 50 mg twice weekly for 3 months, followed by a maintenance dose of 50 mg weekly. In children, doses of 0.8 mg/kg are used (up to a maximum of 50 mg) weekly. For PsA the recommended dose of etanercept is 50 mg weekly. This article will review available data on long term efficacy and safety of etanercept in PsO and PsA.
all three comparisons). At week 24, the percentage of patients achieving PASI 75 increased to 59%, 44%, and 25% of patients in the 50 mg BIW, 25 mg BIW, and 25 mg QW groups, respectively. Twenty-eight percent of the 652 randomized study subjects did not reach PASI 50 at any point during the trial (PASI 50 nonresponders) and were enrolled in a 36-week open label extension receiving 50 mg QW.\(^{14}\) During the 36-week open label extension, 72% and 38% of subjects received treatment through to at least week 48 (week 24 of open label extension) and week 60 (week 36 of open label extension), respectively. At week 36 (week 12 of open label extension), 43% of the PASI 50 nonresponders achieved PASI 50 or better response, and at week 60 (week 36 of open label extension), 55% and 23% of subjects achieved PASI 50 and PASI 75 responses, respectively. The mean percentage improvement for this group of PASI 50 nonresponders increased from 26.6% at week 24 (open label baseline) to 49.3% at week 60 (open label week 36). The quality of life, assessed by the Dermatology Life Quality Index (DLQI) showed a mean improvement of 38.8% from the initial baseline (Table 1).

In 2007, Tyring et al published data on the 84-week open label extension\(^ {15}\) of a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of 50 mg BIW of etanercept versus placebo at 12 weeks.\(^ {16}\) In the open label extension, 591 of the original 618 subjects received etanercept 50 mg BIW for an additional 84 weeks, regardless of their treatment group prior to week 12.

### Table 1 Long term etanercept efficacy in psoriasis

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Duration</th>
<th>Patients</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krueger et al(^ {14})</td>
<td>Open label extension of Phase III trial for nonresponders</td>
<td>60 weeks</td>
<td>157</td>
<td>PASI 50: 55%, PASI 75: 23% at 60 weeks (PASI 50 nonresponders at week 24)</td>
</tr>
</tbody>
</table>
| Tyring et al\(^ {15}\)  | Phase III trial                                                      | 96 weeks       | 591      | a) Placebo/etanercept group: PASI 50/75/90: 79.1%, 51.6%, and 22.8% at 96 weeks  
|                |                                                                    |                |          | b) Etanercept/etanercept group: PASI 50/75/90: 82.6%, 51.1%, and 23.2% at 96 weeks |
| Leonardi et al\(^ {19}\) | Extension of two Phase III trials                                   | 48 up to 72 weeks | 912      | a) 50 mg QW, no dose escalation group: PASI 50/75/90: 90%, 60%, and 27% at 72 weeks  
|                |                                                                    |                |          | b) 50 mg BIW, dose escalation group: PASI 50/75/90: 83%, 43%, and 10% at 72 weeks |
| Paller et al\(^ {72}\)  | Open label extension of Phase III trial (Pediatric)                 | 96 weeks       | 140      | PASI 50/75/90: 89%, 61%, and 30% at week 96  
| Papp et al\(^ {20}\)   | Post hoc analysis                                                   | Up to 4 years  | 506      | PGA clear or almost clear 29.2% and 27.8% at 48 months  
| Esposito et al\(^ {20}\) | Retrospective                                                       | 156 weeks      | 61       | PASI 75: 83.61% at week 156                      |

Abbreviations: PASI, Psoriasis Area and Severity Index; PGA, Physicians Global Assessment; QW, once weekly; BIW, twice weekly.
to week 13. At week 24 (week 12 of open label extension) in the placebo/etanercept group, subjects achieved clinical improvement comparable to those patients in the original etanercept group at week 12. By week 96, PASI 50, PASI 75, and PASI 90 response rates were 79.1%, 51.6%, and 22.8%, respectively, for the placebo/etanercept group and 82.6%, 51.1%, and 23.2%, respectively, for the etanercept/etanercept group. PASI 75 responses reached a plateau at week 48 and of the subjects who achieved a PASI 75 response at week 48 and were reevaluated at week 96, 74.4% maintained a PASI 75 response. Among the reasons for the observed loss of efficacy was lack of patients’ adherence to the therapeutic regimen. In patients who were less than 90% adherent to therapy, responses declined by more than 20% from week 48 to 96, in comparison with a decrease of only 10% in patients with at least 90% adherence. Of the subjects who did not achieve a PASI 75 at week 48, 17.4% were PASI 75 responders at week 96. Mean baseline DLQI scores for the placebo/etanercept and etanercept/etanercept groups were 12.5 and 12.1, respectively, and at week 96 those values had decreased to 3.7 and 3.5, respectively, with the only statistically significant DLQI response rates occurring at week 12 between the treatment and placebo groups (77% versus 40%, \( P < 0.001 \)). Of note, during the initial 12 week study, fatigue and depression were assessed with the functional assessment of chronic illness therapy fatigue (FACT-F) scale, the Hamilton Depression Rating Scale (Ham-D), and the Beck depression inventory (BDI). BDI and Ham-D improvement rates were 55% for the etanercept group versus 39% for the placebo group (\( P = 0.001 \)) and 43% for the etanercept group versus 32% for the placebo group (\( P = 0.0048 \)), respectively. Furthermore, fatigue scores also improved showing at week 12 that patients receiving etanercept had an improvement in FACT-F of 58% compared with 43% in those receiving placebo (\( P = 0.0001 \)). Interestingly, 18.3% of patients in this long term study were found to have anti-etanercept antibodies. However, these antibodies were determined to be nonneutralizing and did not appear to affect efficacy of treatment. Although this figure of 18.3% of subjects was higher than previously reported proportions (approximately 6% of adult patients with rheumatoid arthritis, PsA, ankylosing spondylitis, or plaque PsO), all prior studies also indicated that these antibodies had no effect on efficacy or safety profiles.

Two randomized, double-blind, placebo-controlled, multicenter American and global Phase III trials, were followed by an open label extension study published in 2010 by Leonardo et al. In this study, subjects initially received 50 mg etanercept QW for the first 12 weeks. Thereafter, eligible patients could maintain the 50 mg QW dose or escalate to 50 mg BIW based on a lack of clinical response (inability to achieve of PASI 75, significant residual disease, or residual disease in highly aesthetic or functional areas of significance) and continue the chosen therapy for up to 72 weeks. Of the 912 subjects enrolled in the extension study, 818 (89.7%) completed 48 weeks of treatment, and 485 subjects (53.2%) completed 72 weeks of treatment. Five hundred ninety-one subjects (64.8%) increased their dose to 50 mg BIW at some point after week 12 while the remaining 321 subjects (35.2%) maintained their dose at 50 mg QW. The mean weights were higher in the increased dose versus maintained dose groups (93.2 kg versus 87.6 kg). Similarly, baseline mean PASI scores of the parent (19.5 versus 17.7) and extension studies (6.3 versus 8.8–8.9) were higher in the increased dose group compared to the maintained dose group. In the maintained dose group, the percentage improvement in the mean PASI score was 65% at baseline of the extension and 75%, 77%, and 75% at weeks 12, 48, and 72, respectively, while mean percentage of improvement in the mean PASI score for the increased dose group was 54% at baseline and 60%, 67%, and 67% at weeks 12, 48, and 72, respectively. Furthermore, a Physician’s Global Assessment (PGA) score of 0 or 1 remained stable during the extension and was achieved by 54% and 51% of subjects at weeks 48 and 72, respectively, in the maintained dose group. In the increased dose group, a PGA score of 0 or 1 was achieved by 28% of subjects who increased their dose at week 48 and 27% at week 72. In subjects without dose escalation, PASI 50, 75, and 90 were observed in 90%, 60%, and 27%, respectively, at week 72. In the increased dose group, PASI 50, 75, and 90 responses were observed in 83%, 43%, and 10% of subjects, respectively, at week 72. Mean DLQI scores were improved by 55% at baseline of the extension, by 76% at 48 weeks in the maintained dose group, and by 45% and 64% at baseline and week 48, respectively, in the increased dose group.

In 2012 Papp et al performed a post hoc analysis on prospective efficacy and safety data for up to 4 years of etanercept use in PsO from a cohort of 506 Canadian patients who had participated in at least one of four previous studies. Subjects had received either etanercept 25 mg BIW, 50 mg QW, or 50 mg BIW, based on the trial with which they had commenced therapy. This study represents the longest published experience to date as previously published data did not extend beyond 2.5 years. Effectiveness endpoints were changes from baseline DLQI and static PGA scores completed at 3 month intervals throughout the course of the
long term efficacy was evaluated in a previously published study, in which 169 patients continued treatment with subcutaneous etanercept 25 mg BIW for up to 48 weeks. Subject response to therapy was determined using 20% improvement in the American College of Rheumatology scores (ACR) 20 together with radiographic progression of disease as determined by the Sharp method modified to include joints frequently affected by PsA, PsA response criteria (PsARC), and PASI scores. ACR 20 was achieved by 64% and 63% of those initially assigned to either etanercept or placebo, respectively, while 44% and 49%, respectively, achieved ACR 50 (Table 2). These results were similar to those found in the initial study, and were sustained until week 48. ACR 20 and ACR 50 responses were comparable in both groups subsequent to week 12. The PsARC criteria were achieved by 80% of the patients assigned originally to etanercept. The patients assigned to placebo achieved similar results.

**Table 2 Long term etanercept efficacy in psoriatic arthritis**

<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Duration</th>
<th>Patients</th>
<th>Patients</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mease et al[26]</td>
<td>Phase III trial</td>
<td>Up to 48 weeks</td>
<td>205</td>
<td>a) Placebo/etanercept group: ACR 20: ∼25%, ACR 50: ∼5%, PsARC: 23% at week 24; b) Etanercept group: ACR 20: ∼60%, ACR 50: ∼40%, PsARC: 70% at week 24</td>
<td></td>
</tr>
<tr>
<td>Mease et al[27]</td>
<td>Extension of Phase III trial</td>
<td>Up to 2 years</td>
<td>169</td>
<td>a) Placebo/etanercept group: ACR 20: 63%, ACR 50: 49%, PsARC: 80% at 96 weeks; b) Etanercept group: ACR 20: 64%, ACR 50: 44%, PsARC: 84% at 96 weeks</td>
<td></td>
</tr>
<tr>
<td>Esposito et al[28]</td>
<td>Retrospective</td>
<td>156 weeks</td>
<td>61</td>
<td>a) Placebo/etanercept group: DAS44-ESR score decreased from 5.80 to 0.89 at 156 weeks; b) Etanercept group: ACR 20: 63%, ACR 50: 49%, PsARC: 80% at 96 weeks</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ACR 20, Improvement in the American College of Rheumatology scores by 20%; ACR 50, Improvement in the American College of Rheumatology scores by 50%; DAS, Disease Activity Score; DAS44-ESR, rheumatologic disease activity in 44 joints plus the erythrocyte sedimentation rate; PsARC, psoriatic arthritis response criteria.
subsequent to 12 weeks of etanercept, a result maintained throughout the length of the study. Patients originally assigned to etanercept maintained an inhibition of radiologic progression for up to 2 years of treatment. Mean adjusted Total Sharp Score from baseline to 2 years was −0.38. In patients originally assigned to placebo, radiographic disease progression was decreased subsequent to etanercept initiation. The decrease in Total Sharp Score between the first and second year, in patients assigned first to placebo and then to etanercept, was comparable to the response observed after 1 year in patients originally treated with etanercept. In terms of radiographic disease progression, the addition of methotrexate or corticosteroids to treatment did not appear to show any significant differences. There is no clear consensus as to whether the use of methotrexate improves drug survival by decreasing adverse events (AEs). The percentage of patients showing no radiographic disease progression was higher in the group assigned to etanercept earlier. These studies showed long term efficacy of etanercept in treatment of PsA and its beneficial effect on prevention of further radiographic disease progression. Regarding response predictors, a recent study showed that higher baseline levels of complement component 3 and C-reactive protein levels are associated with non response to anti-TNF treatments. Results from the Danish registry report that high C-reactive protein levels are associated with good treatment responses to anti-TNF agents.

Safety

The long term safety profile of etanercept has been examined in patients with moderate to severe plaque PsO for up to 4 years in a series of connected trials, reviews of the literature, and a registry of patients. Krueger et al performed an open label extension study with PsO patients (n=157) who did not achieve PASI 50 during the initial clinical trial. Etanercept 50 mg QW was well tolerated in the PASI 50 nonresponders for up to 60 weeks. Exposure-adjusted rates (EARs) of all AEs and infections were similar to those observed during the initial 12-week double-blind portion of the study. During the 60 week extension, most AEs were of mild to moderate intensity. Four patients had injection site reactions (3, mild intensity; 1, moderate). Seven patients discontinued the open label study because of AEs. One patient had a serious infection (cellulitis), and one patient died approximately 1 month after the last dose of the study drug. The death was not considered to be related to study treatment (Tables 3–5).

In a study by Tyring et al, subjects were treated for the first 96 weeks with 50 mg of etanercept BIW totaling 908.9 patient-years (PY) of exposure over the course of the study. Injection site reactions occurred more frequently in patients treated with etanercept. Although overall EARs were similar among the two groups, EARs of noninfectious AEs for placebo and etanercept exposures were 418.8 and 158.0 events per 100 PY, respectively, and the EARs for serious noninfectious AEs were 6.1 and 7.7 events per 100 PY, respectively. The most common serious noninfectious AEs reported for etanercept exposure were MI (0.4 events per 100 PY), basal cell carcinoma (BCC) (0.3 events per 100 PY), and depression (0.3 events per 100 PY) (Table 4). None of these common, serious noninfectious AEs were reported after placebo exposure.

The EARs of infections and serious infections were similar between placebo and etanercept exposures (130.5 and 103.9 events per 100 PY and 1.5 and 1.2 events per 100 PY, respectively). The most frequent type of infection was upper respiratory tract infection at 24.3 and 20.2 events per 100 PY for placebo and etanercept exposures, respectively. Ten

---

**Table 3 Long term safety of etanercept**

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Duration</th>
<th>Patients</th>
<th>AEs (noninfectious)</th>
<th>SAEs (noninfectious)</th>
<th>Infections</th>
<th>Serious Infections</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krueger et al</td>
<td>Psoriasis</td>
<td>60 weeks</td>
<td>157</td>
<td>212</td>
<td>14</td>
<td>183</td>
<td>1 (cellulitis)</td>
<td>1</td>
</tr>
<tr>
<td>Tyring et al</td>
<td>Psoriasis</td>
<td>96 weeks</td>
<td>591</td>
<td>158/100 patient-years</td>
<td>7.7/100 patient-years</td>
<td>103.9/100 patient-years</td>
<td>1.2/100 patient-years</td>
<td>0.2/100 patient-years</td>
</tr>
<tr>
<td>Leonardi et al</td>
<td>Psoriasis</td>
<td>48 up to 72 weeks</td>
<td>912</td>
<td>135.7/100 patient-years</td>
<td>5.6/100 patient-years</td>
<td>95.2/100 patient-years</td>
<td>1.6/100 patient-years</td>
<td>13</td>
</tr>
<tr>
<td>Pariser et al</td>
<td>Psoriasis</td>
<td>Up to 144 weeks</td>
<td>4,410</td>
<td>194/100 patient-years</td>
<td>6.7/100 patient-years</td>
<td>97.8/100 patient-years</td>
<td>1.2/100 patient-years</td>
<td>13</td>
</tr>
<tr>
<td>Kapp et al</td>
<td>Psoriasis</td>
<td>Up to 4 years</td>
<td>506</td>
<td>1,914</td>
<td>90</td>
<td>96.9/100 patient-years</td>
<td>0.9/100 patient-years</td>
<td>2</td>
</tr>
<tr>
<td>Kimball et al</td>
<td>Psoriasis</td>
<td>Up to 3 years</td>
<td>2,511</td>
<td>–</td>
<td>208</td>
<td>–</td>
<td>82</td>
<td>30</td>
</tr>
</tbody>
</table>

**Abbreviations:** AEs, adverse events; SAEs, severe adverse events.
### Table 4 Long term risk of malignancies

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Duration</th>
<th>Patients</th>
<th>All malignancies</th>
<th>Malignancies (excluding NMSC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krueger et al</td>
<td>Psoriasis</td>
<td>60 weeks</td>
<td>157</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Tyring et al</td>
<td>Psoriasis</td>
<td>96 weeks</td>
<td>591</td>
<td>23 (expected 26 SIR [95% CI] 0.88 [0.56–1.33])</td>
<td>9 (expected 4.77 SIR [95% CI] 1.89 [0.86–3.58])</td>
</tr>
<tr>
<td>Leonardi et al</td>
<td>Psoriasis</td>
<td>48 up to 72 weeks</td>
<td>912</td>
<td>1.5/100 patient-years (expected 1.9–2.9/100 patient-years for less severe and severe psoriasis patients respectively)</td>
<td>N/A</td>
</tr>
<tr>
<td>Pariser et al</td>
<td>Psoriasis</td>
<td>Up to 144 weeks</td>
<td>4,410</td>
<td>86</td>
<td>30 (expected 26.05 SIR [95% CI] 1.15 [0.78–1.64])</td>
</tr>
<tr>
<td>Papp et al</td>
<td>Psoriasis</td>
<td>Up to 4 years</td>
<td>506</td>
<td>19 total 1.5/100 patient-years</td>
<td>7 (expected 7.67 SIR [95% CI] 0.91 [0.37–1.88])</td>
</tr>
<tr>
<td>Kimball et al</td>
<td>Psoriasis</td>
<td>Up to 3 years</td>
<td>2,511</td>
<td>87</td>
<td>39 (expected 40.1 SIR [95% CI] 0.97 [0.69–1.33])</td>
</tr>
</tbody>
</table>

The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Minnesota-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Arizona-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Arizona-based data (a less sun-exposed population). The number of observed BCCs was significantly lower in the Arizona-based data (a highly sun-exposed population), but it was significantly different from the expected number in the Arizona-based data (a less sun-exposed population).
than the expected number in the Arizona-based study.\textsuperscript{19} Nonneutralizing antibodies to etanercept were detected in 15.2\% of patients. The safety of etanercept appeared to be similar in patients who tested positive for antibodies to etanercept when compared with those who tested negative.\textsuperscript{19}

In a long term review, Pariser et al analyzed short and long term safety of etanercept to determine the associated risk with higher doses or extended exposure.\textsuperscript{35} The study involved 4,410 patients and the total number of years of exposure was 4,775.1. The rates of noninfectious and infectious AEs did not increase as the dose of etanercept increased. Moreover, the rates of AEs did not increase over time. The rates of serious noninfectious and infectious AEs were similar between the etanercept treatment groups analyzed; they were also stable over time and the AE rates reported in the long term analyses are consistent with those reported in the short term analyses. The most commonly reported noninfectious AEs were headache, arthralgia, injection site hemorrhage, and back pain. The most commonly reported infectious AEs were upper respiratory tract infection, nasopharyngitis, sinusitis, and influenza. Data analysis with respect to malignancies showed an increased risk for developing SCC.

The Papp et al\textsuperscript{36} post hoc study analyzed a total of 1305.4 PY of etanercept exposure. The EARs for all AEs and SAEs were 243.5 and 7.8 events per 100 PY, respectively. The EAR for all AEs was decreased for every year on therapy, although the rates of SAEs were sustained. The most common SAE included MI (0.6 events per 100 PY) and BCC (0.3 events per 100 PY). The rate of SAEs occurred at a rate smaller than 1.0 event per 100 PY of exposure. The EAR for all infectious and serious infectious AE at study completion was 96.9 and 0.9 events per 100 PY, respectively. Infection rates were similar while on etanercept therapy, regardless of the dose received. No cases of tuberculosis or opportunistic infections were reported. Nineteen malignancies (EAR of 1.5 per 100 PY) were reported at study completion and were not considered to be related to etanercept. The incidence rate of all malignancies, excluding nonmelanoma skin cancer (NMSC), observed at study completion was consistent with the expected rate in the general population. No statistically significant difference was seen between the observed and expected rates of BCC and SCC with either comparator database. EARs for all reported cardiovascular events (n=37) and serious cardiovascular events (n=22) were 2.8 and 1.7 events per 100 PY, respectively. There was no apparent association of MI or cerebrovascular accident with respect to length of exposure to etanercept. Two other deaths were reported in the cohort.

The OBSERVE-5 interim analysis evaluated data from 2,511 patients initially enrolled in a registry for up to 3 years.\textsuperscript{36} A total of 145 patients discontinued etanercept because of one or more AEs; the most common of these events were cellulitis (n=8), pneumonia (n=8), hypoadiposia (n=6), paresthesia (n=5), dysnea (n=4), and worsening PsO (n=4). Thirty patients died during the follow-up period. However, the relationship of these deaths to etanercept was thought to be unrelated to etanercept. A total of 290 patients had one or more SAEs, including 82 patients with one or more serious infectious events and 61 patients with one or more serious infectious events requiring hospitalization. A total of 459 patients had one or more events of medical interest. The number of events of NMSC, lymphoma, and all cancers combined excluding NMSC and serious infectious events requiring hospitalization in this registry was not higher than that expected for patients with PsO using nonbiologic systemic therapies when compared to data from a large administrative health claims database.\textsuperscript{36} Four-year data from this registry is pending publication.

Several studies have also evaluated safety and efficacy of retreating patients after discontinuing etanercept. One study with 2,546 patients evaluated continuous versus interrupted

### Table 5 Events of medical interest

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Duration</th>
<th>Patients</th>
<th>CHF</th>
<th>Demyelination</th>
<th>Lymphoma</th>
<th>Oportunistic infection</th>
<th>TB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krueger et al\textsuperscript{14}</td>
<td>Psoriasis</td>
<td>60 weeks</td>
<td>157</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tyring et al\textsuperscript{19}</td>
<td>Psoriasis</td>
<td>96 weeks</td>
<td>591</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leonardi et al\textsuperscript{19}</td>
<td>Psoriasis</td>
<td>48 up to 72 weeks</td>
<td>912</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pariser et al\textsuperscript{35}</td>
<td>Psoriasis</td>
<td>Up to 144 weeks</td>
<td>4,410</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1 (esophageal candidiasis)</td>
<td>0</td>
</tr>
<tr>
<td>Papp et al\textsuperscript{36}</td>
<td>Psoriasis</td>
<td>Up to 4 years</td>
<td>506</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Kimball et al\textsuperscript{37}</td>
<td>Psoriasis</td>
<td>Up to 3 years</td>
<td>2,511</td>
<td>0</td>
<td>6</td>
<td>2 (expected 2.3 SIR [95% CI] 0.88 [0.11–3.17])</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CHF, congestive heart failure; CI, confidence interval; SIR, standardized incidence ratio; TB, tuberculosis.
treatment with etanercept 50 mg weekly after 12 weeks of treatment with etanercept 50 mg BIW. The primary endpoint was a PGA ≤2, and loss of response was defined at PGA >2. In the interrupted treatment group, patients were restarted after loss of response. The proportion of responders was higher in the continuous treatment group (71.0% versus 59.5%, P<0.0001) with a similar rate of AEs and SAEs in both groups. A separated trial evaluated interruption of etanercept after 24 weeks and showed that after 12 weeks of retreatment, severity scores were similar to those initially obtained in the first 12 weeks of treatment. Treatment was restarted after loss of 50% of PASI response seen previously at week 24. A post hoc analysis evaluated the retreatment response of 226 moderate to severe PsO patients. Patients were treated with etanercept 50 mg BIW and discontinued treatment after 12 weeks or upon achieving PGA ≤2. Treatment with etanercept 25 mg BIW was restarted for up to 24 weeks or after achieving a PGA score of ≥3. Eighty-three percent of the patients recaptured a clinical response of a PGA ≤2 after retreatment. No safety concerns appeared to be associated with retreatment and no events of special medical interest (eg, tuberculosis, histoplasmosis, or demyelinating disease) were reported (Table 5).

In two large PsA trials, subjects showed AEs and infections at similar rates in both the etanercept and placebo groups during the initial 24 week period. Most events were of mild or moderate intensity. SAEs occurred in four patients in the etanercept group and included chest pain, renal calculus, syncope, and multiple sclerosis. In the placebo group, four patients experienced SAEs, including one patient who died. Laboratory abnormalities were of mild or moderate intensity during the study. During the 24-week open label extension, AEs and infections occurred at comparable or lower rates than those observed during the initial 24 weeks, with no deaths reported. No anti-etanercept antibodies were detected in any patient in the study. During the 48 weeks of the extension study, there were also no deaths. SAEs were reported in 19 patients. All were considered unrelated to etanercept except for one patient who developed pneumonia. Rates per PY of upper respiratory infection, sinusitis, urinary tract infection, flu syndrome, pharyngitis, and bronchitis were similar to those observed during the randomized phase of the study. Injection site reactions occurred in 10% of patients in the original etanercept group, compared with 27% of patients in the original placebo group. All were mild or moderate in severity. Overall, rates of AEs during the maintenance and open label periods were similar to or lower than those observed during the first 24-week double-blind treatment.

Among the AEs reported in several studies, new onset or paradoxical exacerbations of PsO have been reported with all TNF-α inhibitors, including etanercept. In patients without PsO (eg, rheumatoid arthritis), one study reported that etanercept had the lowest rate of new onset PsO of all of the anti-TNF therapies. It is important to notice that despite these results, medically important events that have been reported with anti-TNF therapies, include, among others, demyelinating diseases, opportunistic infections, and tuberculosis (Table 5). Over the past decade, several registries across the world have gathered long term safety data on the use of biologics in different diseases. The British Society for Rheumatology Biologics Register reported data about the efficacy and safety of TNF-α inhibitors (etanercept, infliximab, and adalimumab) in PsA. Patients treated with etanercept 50 mg/week (n=333) had an improvement of mean Disease Activity Score (DAS) 28 from 6.1 at baseline to 3.3 at 18 months. SAEs in this cohort were not separated by specific treatment. The incidence rate ratios of the TNF-α group when compared with controls was not increased (0.9; 95% CI 0.8–1.3). The Spanish registry of biological therapies in rheumatic diseases (BIOBADASER) reported safety findings concerning the use of biologics in several publications. Their findings showed that AEs related to administration (ARR) of TNF-α antagonists are more common with infliximab (ARR rate of 28 per 1,000 PY) when compared to etanercept or adalimumab (ARR rate of 0.2 per 1,000 PY). Up until 2008, there were three reported cases of demyelinating disease in PsA patients treated with TNF-α inhibitors, none of which was related to etanercept. According to BIOBADASER 2.0, PsA did not increase the risk of developing cancer in patients exposed to TNF-α inhibitors (n=727 patients, bivariate incidence rate ratio 0.97; 95% CI 0.49–1.92).

**Etanercept combination treatment and comparative studies**

**Phototherapy**

The use of etanercept in combination with ultraviolet B (UVB) phototherapy for treating PsO has been evaluated in several short term trials. A 12-week open label study evaluated the efficacy of etanercept 50 mg BIW in combination with narrow band UVB (NBUVB) phototherapy in 86 patients. At week 12, 58.1% of subjects achieved PASI 90 response and 84.9% of subjects achieved PASI 75.

A separate trial comparing the response to etanercept monotherapy versus etanercept plus NBUVB in 13 patients found the reduction in the modified PASI was significantly
higher in the etanercept plus NBVUB group \( (P=0.011, 95\% \text{ CI } -19\% \text{ to } -3\%) \) over a 6 week period.\(^4^7\)

In addition, a retrospective study comparing the efficacy of psoralen plus ultraviolet A (PUVA) light versus etanercept found PUVA responses to be higher than those of etanercept (PASI 90: 69\% and 29\%, PASI 75: 86\% and 39\%, and PASI 50: 89\% and 84\% for PUVA and etanercept, respectively).\(^5^0\) The limitations of this study include the number of patients (PUVA n=118 and etanercept n=38), the retrospective design, and treatment length (12 weeks for etanercept and treatment completion for PUVA). It has been previously established that long term PUVA therapy (>250–300 treatments) increases the risk of NMSC (adjusted relative risk 8.6, 95\% CI 4.9–15.2)\(^5^1\) and melanoma (relative risk 5.4, 95\% CI 2.2–11.1).\(^5^2\) As such, although the combination of phototherapy and etanercept can be clinically useful, this combination should be recommended only for short term use to avoid increasing the risk of skin malignancies.\(^5^3\)

**Methotrexate**

Methotrexate is the most widely used systemic treatment for PsO. Several studies have evaluated its use in conjunction with etanercept. A 24-week randomized, controlled trial assessed the combination of etanercept plus methotrexate to treat PsO.\(^5^4\) At week 24, PASI 75 was achieved in 77.3\% versus 60.3\% \( (P<0.0001) \) of patients in the etanercept plus methotrexate versus the etanercept monotherapy group, respectively.\(^5^4\) Although the AE rate was higher in the combination group, the combination therapy proved to be safe and more effective than monotherapy.\(^5^4\)

A separate trial of 440 subjects with PsA evaluated the efficacy of the combination of anti-TNF agents (etanercept, infliximab, and adalimumab) and methotrexate.\(^5^5\) Of the 440 subjects, 170 received anti-TNF monotherapy while 270 received an anti-TNF therapy plus methotrexate. The study did not show a significant clinical difference (DAS 28 and ACR) between the two groups after 12 months. This study also showed drug survival was significantly better in the anti-TNF plus methotrexate (MTX) group during the first 2 years of treatment and did not show statistical significance at year 3 \( (P=0.07) \). A stratified analysis of the three anti-TNF agents used in the study showed statistically significant differences between the monotherapy and the MTX comedication groups in patients receiving infliximab and adalimumab, favoring comedication. These differences in drug survival were not seen in both groups treated with etanercept alone or when combined with MTX.

A second study in subjects with PsA compared radiographic progression between patients treated with anti-TNF-\(\alpha\) agents versus methotrexate monotherapy.\(^5^6\) A total of 65 patients were treated with TNF-\(\alpha\) inhibitors, of which 46 received etanercept compared to 70 patients who were treated with methotrexate. TNF-\(\alpha\) inhibitors were more efficacious than methotrexate in the inhibition of radiographic joint damage progression (88\% versus 61\%, \( P=0.005 \)).\(^5^6\)

**Cyclosporine**

In a clinical study from 2010, seven patients with recalcitrant PsO were treated with a combination of etanercept and cyclosporine 200 mg daily with a 93.2\% PASI improvement (mean time 56.5 weeks). There were no reports of SAEs during this trial.\(^5^7\)

A separate 24-week open label study added concomitant cyclosporine 3 mg/kg/day in PsA patients whose joint symptoms had improved on etanercept monotherapy but whose PASI scores were still greater than 10.\(^5^8\) After 24 weeks of combined treatment, nine of these eleven patients achieved PASI 75.

Another study in subjects with PsA evaluated etanercept plus cyclosporine versus etanercept plus methotrexate for maintaining clinical control.\(^5^9\) After 6 months, the study showed no significant difference in the mean decrease of DAS 28 with the two associations (etanercept plus cyclosporine 2.64±0.66 versus etanercept plus methotrexate 2.32±0.74, \( P=0.22 \)). Also, no significant difference in SAEs between the two treatment groups was found, except, not surprisingly, for hypertension, which was statistically more frequent in the etanercept plus cyclosporine group.

**Acitretin**

A 24-week randomized, controlled, investigator-blinded trial compared the efficacy of etanercept 25 mg BIW, acitretin 0.4 mg/kg daily, or etanercept 25 mg QW plus acitretin 0.4 mg/kg daily for PsO treatment in 62 patients.\(^6^0\) At 24 weeks, PASI 75 response was achieved in 45\%, 44\%, and 30\% of patients in the etanercept, etanercept plus acitretin, and the acitretin groups, respectively \( (P=0.001 \) for both etanercept groups when compared with acitretin alone). No SAEs were reported.\(^6^0\)

**Comparative studies with other biological agents**

Several comparative studies have analyzed short term efficacy of different biological agents compared to etanercept in the treatment of PsO.\(^6^1\)–\(^6^3\) A 2011 meta-analysis evaluated randomized controlled trials published up to 2008 comparing the efficacy...
of infliximab, ustekinumab, adalimumab, etanercept, and efalizumab in the treatment of moderate to severe PsO. Based on an indirect comparison, predicted mean probability of achieving a PASI 75 of infliximab was 80%, ustekinumab 90 mg was 74%, ustekinumab 45 mg was 69%, adalimumab was 58%, etanercept 50 mg BIW was 52%, etanercept 25 mg BIW was 39%, efalizumab was 26%, and placebo was 4%.

A 2010 study in 903 moderate to severe PsO patients showed that at week 12, PASI 75 was achieved by 73.8% of patients who received ustekinumab 90 mg and by 67.5% of patients who received ustekinumab 45 mg when compared with 56.8% of those who received etanercept (P=0.01 and P<0.001, respectively).62

In the PsA literature, a comparative review evaluated etanercept, adalimumab, infliximab, and golimumab efficacy in PsA treatment.64 No significant differences were found in ACR 20 responses to the four drugs after 24 weeks.

In addition, a large multicenter observational study evaluated the survival rate of anti-TNF-α treatments for PsO.63 From a total of 650 patients, etanercept showed a longer survival (mean 51.4 months, P<0.001) as compared to infliximab (36.8 months) and adalimumab (34.7 months). Treatment discontinuation due to primary and secondary inefficacy was observed in 5.2% and 14.5% of patients, respectively, whereas discontinuation due to AEs was reported in 29 subjects (4.5%).65 These results differ from those found in the Danish study from the Danish nationwide database DERM BIO, in which infliximab held the longest survival rate compared to adalimumab and etanercept.66

Lastly, at the recent Congress of the European Academy of Dermatology and Venereology, results were presented from the FIXTURE study, a randomized, double-blind, placebo-controlled, global multicenter study involving 1,306 patients with moderate to severe PsO who were randomized to receive either secukinumab (an IL-17A inhibitor) 300 mg or 150 mg versus etanercept 50 mg versus placebo.67 At week 12, 54% and 24% of patients taking secukinumab 300 mg had achieved PASI 90 and PASI 100, respectively, as compared with 21% and 4% of etanercept patients. In addition, at week 52, 65% of patients on secukinumab 300 mg had a PASI 90 response as opposed to 33% of etanercept patients. AEs and SAEs were similar between treatment groups throughout the 52-week study, although full data have yet to be published.

Special populations
Geriatric
Fleischmann et al68 assessed safety of etanercept in subjects 65 years of age or older compared with those younger than 65 utilizing data from 18 clinical trials of rheumatoid arthritis, two PsA trials, and two ankylosing spondylitis trials. After gender and exposure adjustments, no significant difference was observed between groups for AEs, SAEs, or serious infections. Militello et al69 analyzed data from two Phase III trials of etanercept treatment for patients with PsO, of whom 77 patients were aged 65 years or older. The study found no statistical differences in rates of PASI 75 and DLQI changes between patients in the older and the younger groups. Rates of SAEs in this study were higher in the older group, but this difference was considered unrelated to etanercept treatment.69 Furthermore, Esposito et al retrospectively evaluated long term efficacy of etanercept in PsO patients older than 65 years.70 At week 156, PASI 75 was achieved in 84% of the 61 study subjects. The mean score used to assess rheumatologic disease activity in 44 joints plus the erythrocyte sedimentation rate decreased from 5.80 to 0.89 at 156 weeks of treatment. Etanercept was well tolerated during the study.

Pediatrics
Paller et al evaluated long term safety and efficacy of etanercept in pediatric patients (ages 4–17 years) with moderate to severe PsO in an open label extension from a previous 48 week etanercept study.71,72 Patients were dosed by weight and received etanercept 0.8 mg/kg QW. One hundred and eighty two subjects participated in the study and 140 (76.9%) completed the study through to week 96. PASI 50, 75, and 90 at week 96 were 89%, 61%, and 30%, respectively, figures that were superior to those previously discussed in the adult population study. Thus, in our obese PsO population (both adolescents and adults) weight-based dosing would be of value.71,72 After 96 weeks, etanercept was generally well tolerated. The most common AE was upper respiratory tract infections (24.9%), nasopharyngitis (17.1%), streptococcal pharyngitis (12.7%), headache (11.6%), and sinusitis (10.5%). No deaths, severe or opportunistic infections, or malignancies were observed. The number of SAEs was similar to that reported in the initial 48-week study.72

Pregnancy and lactation
Etanercept is labeled as category B by the US Food and Drug Administration ranking of drug use in pregnancy. There are no studies in pregnant or breastfeeding women. Data from a registry of patients with rheumatic diseases and PsO showed that out of 144 pregnant patients, the percentage of infants with major birth defects among all births was 8% for the etanercept exposed patients and 5.7% for the controls.8 In a case report,
fetal serum from of a pregnant patient treated with etanercept 25 mg BIW was approximately one thirtieth of the maternal levels. With respect to breastfeeding, serum concentrations of etanercept were recorded immediately after delivery and at weeks 1 and 3 postpartum. The infants’ serum etanercept concentrations were 81, 21, and 2 ng/mL immediately after delivery and at weeks 1 and 3, respectively. These data suggest that there are low levels of etanercept transferred to the fetus during pregnancy. However, because etanercept is a relatively large molecule, it would not be expected to be absorbed by a neonate’s immature gastrointestinal system during breastfeeding. Nevertheless, given the observed mild increase in the rate of birth defects, etanercept should be used in pregnancy only if no other options are available. It is important to realize that PsO pregnancies do have a higher risk of side effects versus the normal population.

Conclusion

PsO and PsA are chronic, immune-mediated inflammatory diseases associated with several comorbidities. The evidence of their impact in other organs has led to a major change in the definition of these diseases, once considered only limited to skin and/or joints. Now, both are considered systemic diseases. In the past two decades, our understanding of the pathophysiology of PsO has advanced enormously. These advances have been paralleled by the development of new, highly efficacious therapeutic options. Etanercept is one example of the new era in PsO therapeutics. As with any major advance in medicine, the advent of biological agents has come to fruition because of numerous large scale, multi-center randomized controlled trials to evaluate their efficacy and safety. Over the past decade, etanercept has proven to be efficacious as monotherapy or when used in combination with other PsO treatments. With any new medication, particularly one specifically targeting the immune system, rigorous attainment of safety data has been crucial in providing more appropriate guidelines for treatment. Specifically, various biologically agents have been associated with serious infections such as, tuberculosis and hepatitis B reactivation, demyelinating diseases, lymphomas, leukemia, and NMSC and should be used with caution taking every patient’s specific needs into account. Nevertheless, many of these associations occurred at rates similar to those observed in the general population or at such small rates that the benefit of treating PsO patients clearly outweighs the risks mentioned. It has been two decades since etanercept’s first human trials in 1993, and after almost a decade since its Food and Drug Administration approval, etanercept is still an important and valuable option in any physician’s arsenal for the treatment of moderate to severe PsO and/or PsA.

Disclosure

BM has no conflicts of interest to report. DK has been a speaker for Abbott, and AM has sat on the advisory boards of Abbott, Amgen, Galderma, Janssen, and Wyeth, has been a consultant for Abbott, Amgen, Eli Lilly, Galderma, Janssen, LEO Pharma, Stiefel, and Wyeth, an investigator for Abbott, Allergan, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Novo Nordisk, Pfizer, Stiefel, Syntrix Biosystems, and Wyeth, a speaker for Abbott, Amgen, Galderma, Janssen, LEO Pharma, and Wyeth, and has received grants and/or honoraria from Abbott, Allergan, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Novo Nordisk, Pfizer, Stiefel, Syntrix Biosystems, and Wyeth.

References


67. Langley R. Secukinumab compared with placebo and etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe psoriasis (FIXTURE). Oral presentation at: 22nd Congress of the European Association of Dermatology and Venereology (EADV); October 3; 2013; Istanbul, Turkey.


